US Stock MarketDetailed Quotes
SCNI Scinai Immunotherapeutics
- 5.075
- -0.815-13.84%
Trading Jul 16 10:06 ET
4.26MMarket Cap-317P/E (TTM)
5.600High4.800Low319.56KVolume5.310Open5.890Pre Close1.66MTurnover43.73%Turnover RatioLossP/E (Static)838.58KShares14.20052wk High-0.93P/B3.71MFloat Cap2.23052wk Low--Dividend TTM730.73KShs Float6199.990Historical High--Div YieldTTM13.58%Amplitude2.230Historical Low5.181Avg Price1Lot Size
Scinai Immunotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -39.49%1.93M | -12.25%9.71M | -39.68%1.82M | -2.73%2.1M | -20.47%2.6M | 21.84%3.19M | 1.83%11.06M | -12.26%3.02M | -15.40%2.16M | 19.34%3.26M |
| Selling and administrative expenses | -59.36%484K | -14.94%4.51M | -24.12%1.21M | 0.10%968K | -11.48%1.14M | -17.98%1.19M | -30.54%5.3M | -30.38%1.59M | -49.79%967K | -40.06%1.29M |
| Research and development costs | -21.40%1.57M | -9.63%5.21M | -56.28%627K | -5.03%1.13M | -26.34%1.45M | 71.54%2M | 77.44%5.77M | 22.00%1.43M | 89.96%1.19M | 238.26%1.97M |
| Other operating expenses | ---124K | ---9K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit | 39.49%-1.93M | 12.25%-9.71M | 39.68%-1.82M | 2.73%-2.1M | 20.47%-2.6M | -21.84%-3.19M | -1.83%-11.06M | 12.26%-3.02M | 15.40%-2.16M | -19.34%-3.26M |
| Net non-operating interest income expense | 29.79%-231K | -96.20%115K | 16.89%-3.6M | -24.93%5.21M | -516.79%-1.17M | -335.00%-329K | -3.60%3.03M | -190.16%-4.33M | 2,821.55%6.94M | 129.49%280K |
| Non-operating interest income | ---- | -95.97%123K | ---- | ---- | ---- | ---- | -3.20%3.05M | ---- | ---- | ---- |
| Non-operating interest expense | -29.79%231K | ---- | ---- | ---- | ---- | --329K | ---- | ---- | ---- | ---- |
| Total other finance cost | ---- | -61.90%8K | -49.58%3.72M | 24.93%-5.21M | 516.79%1.17M | ---- | 133.33%21K | --7.38M | ---6.94M | ---280K |
| Other net income (expense) | 38.30%3.09M | 558.93%2.24M | ||||||||
| Gain on sale of security | ---- | 38.30%3.09M | ---- | ---- | ---- | ---- | 558.93%2.24M | ---- | ---- | ---- |
| Income before tax | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -26.11%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | 19.02%-2.98M |
| Income tax | ||||||||||
| Net income | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -26.11%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | 19.02%-2.98M |
| Net income continuous Operations | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -26.11%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | 19.02%-2.98M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -26.11%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | 19.02%-2.98M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 38.58%-2.16M | -12.15%-6.5M | 54.46%-2.33M | -34.97%3.11M | -26.11%-3.76M | -42.02%-3.52M | 29.37%-5.8M | -688.08%-5.12M | 270.08%4.78M | 19.02%-2.98M |
| Basic earnings per share | 66.67%-4 | 60.00%-16 | 77.78%-8 | -80.00%8 | 25.00%-12 | 0.00%-12 | 50.00%-40 | -101.24%-36 | 261.00%40 | 56.59%-16 |
| Diluted earnings per share | 66.67%-4 | 60.00%-16 | 77.78%-8 | -80.00%8 | 25.00%-12 | 0.00%-12 | 50.00%-40 | -101.24%-36 | 261.00%40 | 56.59%-16 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
